Adalimumab was more effective in the patients with bio-naive and early Crohn's disease

被引：0
|
作者：
Hisamatsu, T. [1 ]
Matsuoka, K. [1 ]
Naganuma, M. [2 ]
Miyoshi, J. [1 ,3 ]
Inoue, N. [4 ]
Yajima, T. [1 ]
Mizuno, S. [1 ]
Saigusa, K. [1 ]
Nakazato, Y. [1 ]
Mori, K. [1 ]
Takeshita, K. [1 ]
Nanki, K. [1 ]
Kiyohara, H. [1 ]
Iwao, Y. [4 ]
Ogata, H. [2 ]
Kanai, T. [1 ]
机构：
[1] Keio Univ, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Tokyo, Japan
[2] Keio Univ, Ctr Diagnost & Therapeut Endoscopy, Tokyo, Japan
[3] Tokyo Dent Univ, Ichikawa Gen Hosp, Dept Internal Med, Ichikawa, Japan
[4] Keio Univ, Ctr Prevent Med, Tokyo, Japan
来源：
JOURNAL OF CROHNS & COLITIS | 2014年 / 8卷
关键词：
D O I：
10.1016/S1873-9946(14)60689-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P569
引用
收藏
页码：S305 / S305
页数：1
相关论文
共 50 条
  • [11] Ustekinumab in bio-naive and bio-failure Crohn's disease patients: Results from a "real-life" monocentric cohort
    Monin, L.
    Dubois, S.
    Reenaers, C.
    Van Kemseke, C.
    Latour, P.
    Van Daele, D.
    Vieujean, S.
    Seidel, L.
    Louis, E.
    DIGESTIVE AND LIVER DISEASE, 2021, 53 (01) : 72 - 78
  • [12] REAL-WORLD EFFECTIVENESS OF USTEKINUMAB IN BIO-NAIVE PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE IN CANADA
    Bessissow, Talat
    Narula, Neeraj
    Ma, Christopher
    In, Tracy S.
    Eberg, Maria
    Karra, Kinda
    Belgnaoui, Mehdi
    Jairath, Vipul
    GASTROENTEROLOGY, 2022, 162 (07) : S811 - S811
  • [13] Disease Severity Among Bio-Naive RA Patients on Csdmards
    Harrold, Leslie R.
    Griffith, Jenny
    Litman, Heather J.
    Feng, Hua
    Schlacher, Casey A.
    Kremer, Joel
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [14] Leukocyte Adhesive Function as Potential Predictive Marker for Treatment Response to Vedolizumab Among Bio-naive Patients with Crohn's Disease
    Liu, J.
    Cheng, Q.
    Cao, Q.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1077 - I1078
  • [15] Vedolizumab Outcomes in Real-world Bio-naive Ulcerative Colitis and Crohn's Disease Patients (EVOLVE) in North America
    Yarur, Andres
    Bassel, Marielle
    Stein, Dara
    Kim, Hankyul
    Radulescu, Gabriela
    Lopez, Claudia
    Lissoos, Trevor
    Demuth, Dirk
    Bressler, Brian
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S374 - S374
  • [16] Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn's disease patients (EVOLVE) in Canada: Interim results
    Bressler, B.
    Greenup, A. -J.
    Bassel, M.
    Stein, D.
    Soni, M.
    Radulescu, G.
    Neish, C.
    Khalid, J. M.
    Demuth, D.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S382 - S382
  • [17] Real-World Clinical Effectiveness and Safety of Vedolizumab and Ustekinumab in Bio-Naive Patients With Early Crohn's Disease: Results From the EVOLVE Expansion Study
    Christensen, Britt
    Scharl, Michael
    Bressler, Brian
    Khan, Zaeem
    Halchenko, Yuliya
    Kamble, Pravin
    Adsul, Shashi
    Farhat, Zeinab
    Ferrante, Marc
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S637 - S638
  • [18] Combination therapy of adalimumab with an immunomodulator is not more effective than adalimumab monotherapy in children with Crohn's disease
    Matar, M.
    Shamir, R.
    Turner, D.
    Broide, E.
    Weiss, B.
    Ledder, O.
    Guz-Mark, A.
    Rinawi, F.
    Cohen, S.
    Olivestone, C. Topf
    Shaul, R.
    Ben-Horin, S.
    Assa, A.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S578 - S579
  • [19] Response to Adalimumab Therapy in bio-naive patients and in Infliximab nonresponders: Results of a Phase Illb Clinical Trial
    Lofberg, R.
    Louis, E.
    Reinisch, W.
    Kron, M.
    Camez, A.
    Pollack, P.
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (12) : S27 - S28
  • [20] 5-Year Outcomes of Adalimumab Use in Nationwide Cohort of Bio-Naive Ulcerative Colitis Patients
    Sundararajan, Ramaswamy
    Patel, Manthankumar
    Trivedi, Chinmay
    Khan, Nabeel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S907 - S907
12345